-

09:52:38 PM

SRPT Stock News

SRPT - Sarepta Therapeutics Inc

06/30/22 6:15 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s

RHEA-AI

very positive

06/23/22 4:01 PM

Nasdaq : SRPT

Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a

RHEA-AI

neutral

06/02/22 4:05 PM

Nasdaq : SRPT

management

Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers and Dr. Boor bring

RHEA-AI

neutral

06/02/22 8:30 AM

Nasdaq : SRPT

conferences

Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on

RHEA-AI

neutral

05/31/22 6:15 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014

RHEA-AI

very positive

05/04/22 4:05 PM

Nasdaq : SRPT

earnings

Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments

Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2022 totaled $210.8 million Net product revenues for the first quarter 2022 totaled $188.8 million, a 51% increase over the same quarter of prior year CAMBRIDGE, Mass., May 04, 2022 (GLOBE

RHEA-AI

neutral

05/04/22 8:30 AM

Nasdaq : SRPT

conferences

Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May

RHEA-AI

neutral

04/29/22 6:23 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 29, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s

RHEA-AI

very positive

04/27/22 8:30 AM

Nasdaq : SRPT

earnings

Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial results after the Nasdaq Global Market closes on Wednesday, May 4, 2022. Subsequently, at 4:30 p.m.

RHEA-AI

neutral

03/31/22 6:30 PM

Nasdaq : SRPT

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

SRPT Data

Websitewww.sareptatherapeutics.com
CeoDouglas Ingram
Security nameSarepta Therapeutics Inc
Issue typecs
Sic code2834
Employees866
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address215 1st St Ste 415
StateMassachusetts
CityCambridge
Zip02142-1213
CountryUS
Phone16172744000

About Sarepta Therapeutics Inc

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.